# DC Vaccine for Patients With Ductal Carcinoma In Situ

> **NCT02061332** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 58 (actual)

## Conditions studied

- Breast Cancer
- DCIS

## Interventions

- **BIOLOGICAL:** HER-2 Pulsed Dendritic cell Vaccine

## Key facts

- **NCT ID:** NCT02061332
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2014-08-08
- **Final completion:** 2015-10-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02061332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02061332, "DC Vaccine for Patients With Ductal Carcinoma In Situ". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02061332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*